Investigating how RBFOX2 affects pancreatic cancer progression through splicing changes
Official title: RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11079453 · Data updated 2026-11-12
This study is looking at a protein called RBFOX2 to see how it affects pancreatic cancer and how changes in the way genes are spliced might make the cancer grow and spread more aggressively, which could help find new ways to treat the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | April 15, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $461,101 |
| NIH project number | 5R01CA279713-03 |
| Project ID | NIH-11079453 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma, particularly those with aggressive or poorly differentiated forms of the disease.
✕Less likely to help
Patients with other types of cancer or those without a diagnosis of pancreatic cancer may not benefit from this research.
What this research studies
This research focuses on understanding the role of the RBFOX2 protein in pancreatic cancer, particularly how its deregulation influences cancer progression through alternative splicing of RNA. By using advanced genetic screening techniques, the study aims to identify specific splicing events that contribute to the aggressiveness of pancreatic ductal adenocarcinoma (PDAC). The researchers will explore how changes in splicing patterns can affect cancer cell behavior, including their ability to invade and differentiate. This work could lead to new insights into the mechanisms of pancreatic cancer and potential therapeutic targets.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for treating pancreatic cancer by targeting the splicing mechanisms involved in its progression.
How similar studies have gone: While the specific role of RBFOX2 in pancreatic cancer is being explored in this research, similar studies have shown that targeting splicing mechanisms can be effective in other cancer types, indicating potential for success.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Mann, Karen M — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Mann, Karen M
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.